Year: 2025

TORONTO, Aug. 13, 2025 (GLOBE NEWSWIRE) — Mattr Corp. (“Mattr” or the “Company”) (TSX: MATR) reported today its operational and financial results for the three and six months ended June 30, 2025. This press release should be read in conjunction with the Company’s Management Discussion and Analysis (“MD&A”) and interim consolidated financial statements for the six months ended June 30, 2025, which are available on the Company’s website and at www.sedarplus.ca. Highlights from the second quarter include1:On a continuing operations basis, Mattr delivered revenue of $321 million and operating income of $10 million. Adjusted EBITDA2 increased by 5% from prior year quarter to $42 million; The Connection Technologies segment’s second quarter revenue increased by 99% to $177 million compared to $89 million in the prior year’s...

Not for distribution to U.S. News wire services or dissemination in the U.S. VANCOUVER, British Columbia, Aug. 13, 2025 (GLOBE NEWSWIRE) — The Keg Royalties Income Fund (the “Fund”) (TSX: KEG.UN) is pleased to announce its financial results for the three months ended June 30, 2025 (the “quarter”) and the six months ended June 30, 2025 (“YTD”). On May 5, 2025, the Fund entered into a non-binding letter of intent to which one or more affiliates of Fairfax Financial Holdings Limited (“Fairfax”) will acquire all of the issued and outstanding units of the Fund other than those already owned by Fairfax (including the Exchangeable Partnership units held by KRL), at a purchase price of $18.60 per unit, payable in cash. On June 17, 2025, the Fund entered into an arrangement agreement (the “Arrangement Agreement”) with 1543965 B.C. Ltd....

– CMT-SORD program advances; meeting scheduled with the FDA in Q3 2025 to discuss govorestat for the treatment of CMT-SORD – Presented full 12-month clinical results and new topline data from INSPIRE Phase 2/3 trial of govorestat for the treatment of CMT-SORD at PNS 2025 Annual Meeting highlighting slowed progression of disease observed via MRI at 24 months – Launched new sponsored Sorbitol Assay to support identification of patients suspected of having CMT-SORD – Entered into out-licensing agreement with Biossil, Inc. for AT-001 – New data on govorestat for the treatment of PMM2-CDG to be presented at the 2025 ASHG Annual Meeting – Ongoing review of govorestat development program for Classic Galactosemia progressing as planned NEW YORK, Aug. 13, 2025 (GLOBE NEWSWIRE) — Applied Therapeutics,...

~ Record Adjusted Gross Margin – 60.6%, up from 42.7% last quarter ~ ~ Strong Adjusted Gross Profit Growth – up 32.7% from last quarter and 71.6% Y/Y ~ ~ Year-over-Year Revenue Growth – $2.35M up 14.2% from Q3 2024 ~ IRVINE, Calif., Aug. 13, 2025 (GLOBE NEWSWIRE) — Mobix Labs, Inc. (Nasdaq: MOBX) (“Mobix Labs” or the “Company”), a leading provider of advanced connectivity solutions, today announced financial results for its third fiscal quarter and nine months ended June 30, 2025. “Mobix Labs delivered one of its strongest quarters ever, achieving record adjusted gross margins, substantial gross profit growth, and a sharp improvement in operating results,” said Phil Sansone, CEO of Mobix Labs. “These results demonstrate the power of our focus on high-margin products, operational discipline, and deep customer relationships in driving...

MISSISSAUGA, Ontario, Aug. 13, 2025 (GLOBE NEWSWIRE) — “Bird continues to execute on its 2025-2027 Strategic Plan, focusing on sectors that have long-term demand drivers, and maintaining a risk balanced and highly collaborative work program that will drive growth and continued margin accretion. Even though the Company’s second quarter was impacted by temporary project delays as our clients adapted to rapidly changing market conditions, these same clients awarded us additional scopes and work packages, giving us confidence that the work programs will proceed in the future once there is greater clarity on cost and economic conditions,” stated Teri McKibbon, President and CEO of Bird Construction. “While Bird’s third quarter is expected to be impacted by similar delays, the Company is well positioned to capitalize on our record $4.6...

TORONTO, Aug. 13, 2025 (GLOBE NEWSWIRE) — Wesdome Gold Mines Ltd. (TSX: WDO, OTCQX: WDOFF) (“Wesdome” or the “Company”) today announced its financial results for the three and six months ended June 30, 2025 (“Q2 2025” and “H1 2025”). Preliminary operating results for Q2 2025 were disclosed in the Company’s press release dated July 14, 2025. Management will host a conference call tomorrow, August 14, 2025 at 10:00 a.m. ET to discuss its results. All amounts are expressed in Canadian dollars unless otherwise indicated. HighlightsImproving Safety Performance: Total Classified Incident Frequency Rate was 0.00 in Q2 2025 and 0.19 for H1 2025, a significant improvement from the 2024 average of 1.34. Production and costs: Consolidated gold production was 42,781 ounces; a 3% decrease compared to Q2 2024. Cost of sales per ounce sold...

August 2025 Monthly Dividend of $0.12 Per Share of Common Stock RMBS Portfolio Characteristics as of July 31, 2025 Next Dividend Announcement Expected September 8, 2025VERO BEACH, Fla., Aug. 13, 2025 (GLOBE NEWSWIRE) — Orchid Island Capital, Inc. (the “Company”) (NYSE: ORC) announced today that the Board of Directors of the Company declared a monthly cash dividend for the month of August 2025. The dividend of $0.12 per share will be paid September 29, 2025 to holders of record of the Company’s common stock on August 29, 2025, with an ex-dividend date of August 29, 2025. The Company plans on announcing its next common stock dividend on September 8, 2025. The Company intends to make regular monthly cash distributions to its holders of common stock. In order to qualify as a real estate investment trust (“REIT”), the Company must...

Announced entry into an agreement to be acquired by XOMA Royalty Corporation for between $1.16 and $1.24 per share in cash, plus a contingent value right related to LAVA’s two partnered assets and unpartnered programs Consummation of acquisition expected to occur in the fourth quarter of 2025, subject to customary closing conditions and an extraordinary general meeting of shareholders Announced decision to discontinue development of LAVA-1266 for acute myeloid leukemia and myelodysplastic syndrome; wind-down of the program has been initiatedUTRECHT, The Netherlands, and PHILADELPHIA, Aug. 13, 2025 (GLOBE NEWSWIRE) — LAVA Therapeutics N.V. (NASDAQ: LVTX, “LAVA,” or the “Company”), a clinical-stage immuno-oncology company historically focused on its proprietary Gammabody® bispecific gamma delta T cell engagers, today announced...